MGTX
MeiraGTx Holdings·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Significant Revenue Decline
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MGTX
Meiragtx Holdings Plc
A US-based clinical-stage gene therapy company developing treatments for rare genetic disorders and ophthalmic diseases
Biological Technology
05/01/2018
06/08/2018
NASDAQ Stock Exchange
375
12-31
Common stock
655 Third Avenue
Suite 1115
New York
NY 10017
--
MeiraGTx Holdings plc was incorporated under the laws of the Cayman Islands on May 1, 2018. The company is a vertically integrated clinical-stage gene therapy company with six clinical development programs and an extensive pipeline of preclinical and research programs. The company has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potential transformational gene regulation platform technology that allows precise, dose-responsive control of gene expression through oral small molecules with a dynamic range of more than 5,000 times. The company's initial focus is on three distinct areas of unmet medical need: eye diseases, including hereditary retinal diseases, large degenerative eye diseases, neurodegenerative diseases and severe xerostomia.
Company Financials
EPS
MGTX has released its 2025 Q3 earnings. EPS was reported at -0.62, versus the expected -0.49, missing expectations. The chart below visualizes how MGTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MGTX has released its 2025 Q3 earnings report, with revenue of 410.00K, reflecting a YoY change of -96.24%, and net profit of -50.51M, showing a YoY change of -28.43%. The Sankey diagram below clearly presents MGTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
